RaDVaC Data Explorer
Antiviral database
Virus Taxonomy
← Back to Dashboard
Ximency
NS3/4A protease + NS5A + NS5B polymerase inhibitors
Constituent drugs (3)
Daclatasvir
Loading structure...
3D not available
Asunaprevir
Loading structure...
3D not available
Beclabuvir
Loading structure...
3D not available
Chemical Identifiers
ClinicalTrials.gov
PubMed
Clinical Development by Virus
1
Hepatitis C virus
HCV
Target: Viral NS3/4A + NS5A + NS5B
Approved (other)
Preclinical
Phase 2
positive
Phase 3
positive
Approved
Japan
Approval ref (kegg.jp)
Approval ref (pmda.go.jp)
PMDA approved 2016/12/19
fixed-dose combination of Daclatasvir, Asunaprevir, Beclabuvir.